Blandino_giovanni_md_cv_january_2013_31[1]

CV Dr. Giovanni Blandino, M.D., MSc - Page 2 Dr. Giovanni Blandino, M.D., M.Sc.

Personal Information

Languages: Italian, English Married: Two children Home Address: Via Apuania 31, 00162 Rome : +39 (06) 4420 2177 +39-339-6825451
Office Address: Translational Oncogenomics Unit Italian National Cancer Institute, Rome “Regina Elena” Via Elio Chianesi 53 00144-Rome Italy : +39 (06) 52665327/2911
Fax: +39 (06) 52662880
E-mail: blandino@ifo.it, gblandino@activep53.eu
CV Dr. Giovanni Blandino, M.D., MSc - Page 3
Academic History
Education
University of Milan, National Cancer Institute, Milan, Italy, 1994 1991 The Italian Association for Cancer Research (AIRC) Fellowship for
1993 The Regina Elena Cancer Institute Fellowship for postdoctoral
1995 The Italian Association for Cancer Research (AIRC) International
1996 The Feinberg Postdoctoral Fellowship, Weizmann Institute of Science
1999 Young Scientist Fellowship From Telethon.

Employment History

Associate Professor, Department of Oncology, McMaster University,
Hamilton Canada, 1st March 2012
Director of Traslational Oncogenomic Laboratory, Italian National
Cancer Institute Regina Elena, Rome Italy, April 2008 –

Institutional Research Coordinator, Translational Oncogenomics Unit,
Italian National Cancer Institute Regina Elena, Rome Italy, April 2007 –2011
Institutional Research Coordinator, Department of Molecular Cell
Biology, Italian National Cancer Institute Regina Elena, Rome Italy, July
2007
Visiting Scientist, Ludwig Institute for Cancer Institute, University of
Oxford, England, September 2010

Fellow Scientist, Department of Molecular Cell Biology Laboratory,
Weizmann Institute of Science, Rehovot Israel, September 2005
CV Dr. Giovanni Blandino, M.D., MSc - Page 4 Medical Researcher, Department of Experimental Oncology, Italian
National Cancer Institute Regina Elena, Rome Italy, January 2002- 2008
Visiting Scientist, Department of Nephrology, Mount Sinai Institute, New
York, USA, June 2001

Telethon Young Fellow, Molecular Oncogenesis Laboratory, Italian
National Cancer Institute Regina Elena, Rome Italy, 1999-2001
Postdoctoral Fellow, Department of Molecular Cell Biology, Weizmann
Institute of Science, Rehovot, Israel, 1995-1999
Postdoctoral Fellow, Italian National Cancer Institute Regina Elena, Rome
Italy, 1991-1995
Fellow, Institute of Pathology, University of Catania, Italy, 1990-1991
Research Student, Institute of Pathology, University of Catania, Italy, 1986-
1990

Licensing
License to practice Medicine in Italy, 1990

Professional Organizations (past and present)
Committee Member: ISF-Israel National Foundation; BSF-Binational USA-
Israel Foundation; CMRH-Netherland Cancer Research; Austrian Cancer Society-Fellowship and Grant Program; Career Program (Associate Professorship) University of Singapore; Dutch Cancer Society; German- Israel Society, North West Cancer Research Fund., AICR, UICC Fellowship Program, Cancer Research UK, AFM-Genethon, Foundation for Polish Science, Weizmann Institute of Science, Health Research Board (HRB)
Journal Reviewer and Editorship

Deputy Editor: Journal of Experimental and Clinical Cancer Research CV Dr. Giovanni Blandino, M.D., MSc - Page 5 Editorial Board Member: The Open Cell Signaling Journal; Journal of Experimental and Clinical Cancer Research; The International Journal of Low Radiation; The European Journal of Clinical and Medical Oncology; World Journal of Otorhinolaryngology (WJO); Reviewer for the following journals: Molecular Cell; PNAS, Blood; Molecular Cell Biology; Cancer Research; Oncogene; Nucleic Acid Research, Cell Death and Differentiation; Molecular Biology of Cell; Genome Biology, Molecular Medicine, Cell Cycle; Leukemia, BMC Molecular Biology; Journal Cell Science, Proteins, FEBS Letters; Journal of Molecular Biology; Experimental Cell Research; British Journal of Pharmacology; Int. Journal of Cancer; Cancer Letters, Molecular Carcinogenesis; Archives Journal of Dermatology; European Journal of Cancer; Cell Proliferation, The Open Cell Signaling Journal, Cell Tissue and Research; BBA; Int. J. of Biochem. Cell. Biol; Oncology; Nature Communications; Tumor Biology; BMC Chemical Biology; Annals of Otology, Rhinology and Laryngology; Breast Cancer Research and
Academic Teaching
Harvard University: University Graduate School Courses Translational Research Methods and Applications (accepted proposed course University lectures at “La Sapienza” University in Rome and University of Teaching Experience

Teacher Basic Science in Oncology (lectures) University La Sapienza (Rome, Teacher, experimental course “Cell cycle and apoptosis”, organized by the international School of Oncology and Experimental Medicine (Rome 1-4 CV Dr. Giovanni Blandino, M.D., MSc - Page 6 Supervisorships

Graduate Students
Sara Donzelli, M.Sc., University of Rome “La Sapienza”, Faculty of
Mathematical, Physical and Natural Sciences, 3 year Degree in Biological
Science, Thesis entitled “Producing cancer cell lines expressing protein mutant
p53 stability”, Rome, Italy, 2002-2005
Sara Donzelli, M.Sc., University of Rome “La Sapienza”, Faculty of
Mathematical, Physical and Natural Sciences, Specializing in Applied Biology
in Biomedical Research, Thesis entitled “Oncogenomic Approaches in
Exploring Gain of Function of Mutant p53”, Rome, Italy, 2005-2007

Federica Ganci, M.Sc., University of “Tor Vergata”, Thesis entitled “The
mutant protein p53His175 controls miR.128b expression in a human large-cell
lung cancer cell line”, Rome, Italy, 2007- 2008

Olimpia Monti, M.Sc., University of “Tor Vergata”, Thesis entitled “p73, p63
and mutant p53: members of protein complexes floating in cancer cells”, Rome,
Italy, 2001- 2002

Ph.D Doctoral Students
Olimpia Monti, M.Sc., University of “Tor Vergata”, Ph.D Thesis entitled “The
disruption of the protein complex mutantp53/p73 increases selectively the
response of tumor cells to anticancer drugs”, Rome, Italy, 2003- 2006
Eleonora Lapi, M.Sc., University of “Tor Vergata”, Ph.D in Molecular and
Cellular Biology, Thesis entitled “Identification of novel and direct target genes
of p73”, Rome, Italy, 2004- 2007

Efrem Bertini, M.Sc., University of “Tor Vergata”, Ph.D in Biochemistry and
Molecular Biology, Thesis entitled “Yap is regulated by phosphorylation at the
G2/M transition”, Rome, Italy, 2006- 2009

Sara Donzelli, M.Sc., University of Rome “La Sapienza”, Faculty of
Mathematical, Physical and Natural Sciences, Ph.D in Genetics and Molecular
Biology, Thesis entitled “Study of mutant p53 protein gain of function by
microRNAs modulation”, Rome, Italy, 2007-2011
Sergio Galanti, M.Sc., University of Rome “La Sapienza”, Faculty of Biology
and Biotechnology “Charles Darwin”, Ph.D in Cell and Developmental Biology,
Thesis entitled “Identification of VDR transcriptional signatures in breast
cancer cells by ChIP-on-chip analysis”, Rome, Italy, 2008-2011
Federica Ganci, M.Sc., Ph.D in Celluar and Molecular Biology, Univeristy of
Tor Vergata, Ph.D Thesis entitled “microRNAs expression profiling in HNSCC
and their correlation with TP53 status”, Rome, Italy, 2008-2011
CV Dr. Giovanni Blandino, M.D., MSc - Page 7
Fabio Valenti, M.Sc., “University of Messina”, Faculty of Mathematical,
Physical and Natural Sciences, Ph.D in Neuroscience, Medicine School
University of Messina, Thesis entitled “Peptide targeted therapies for the
treatment of human cancers with mutations of the p53 gene”, Messina, Italy,
2006-2010
Francesca Fausti, Ph.D in Endocrinology and Molecular Medicine, Thesis
entitled "Role of YAP in apoptosis and senescence processes", Rome, Italy,
2006-2010
Francesca Biagioni, M.Sc., University of Rome “La Sapienza”, PhD
school in Biology and Molecular Medicine, PhD programme in
Immunological Sciences, Thesis entitled “The advent of microRNAs in
the molecular taxonomy of breast cancer”, Rome, Italy, 2006-2009
Stefania Dell’Orso, M.Sc., PhD in Endocrinology and Molecular Medicine,
Faculty of Medicine, University of Rome “La Sapienza”, Thesis entitled
“Application of ChIP on chip analysis to the identification of mutant p53 target
genes”, Rome, Italy, 2006-2009
External Supervisory PhD Committees
Raffaela Santoro, Ph.D in Molecular Oncology, Thesis entitled "The Histone
Acetyl Transferase Tip60 regulates the proapoptotic activities of the
transcription factor E2F1", University of Southern Denmark, Odense, Denmark
2008 (Opponent).
Ying Zhao, Ph.D, Thesis entitled "Pharmacological Targeting of p53 Pathway
Alterations in Tumors", Department of Microbiology, Tumor and Cell Biology,
Karolinska Institutet, Stockholm, Sweden 2010 (Opponent).
Jinfeng Shen, Ph.D, Thesis entitled "Rescue of mutant p53 family members by
the low molecular weight compound PRIMA-1MET/APR-246", Department of
Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet,
Stockholm, Sweden 2010 (Opponent).
Marco Napoli, Ph.D in Molecular Biomedicine, Thesis entitled "A Pin1/mutant
p53 axis promotes aggressiveness in breast cancer", Università degli Studi di
Trieste, Trieste, Italy 2010 (Opponent).
Organization of International conferences
1) Making decisions in G1, Frascati, Italy 2002. 2) 1st International p73/p63 Workshop, Rome, Italy 2002. CV Dr. Giovanni Blandino, M.D., MSc - Page 8 3) 2nd International p73/p63 Workshop, Rome, Italy 2004. 4) P53 Marathon, Ein Gedi, Israel, 2005. 5) 3rd International p73/p63 Workshop, Rome, Italy 2007. 6) P53 Marathon, Lyon, France 2007. 7) P53 Marathon, Acre, Israel 2009; 8) The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, Rome, Italy 22- 23 April, 2009. Published: Blandino G, Shaul Y, Strano S, Sudol M, Yaffe M. The
Hippo tumor suppressor pathway: a brainstorming workshop. Sci Signal. 2009 Nov
3;2(95):mr6.
9) The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, Ariccia (Rome), Italy, 2-5 November 2010. Published: McNeill H, Sudol M, Halder G, Strano S,
Blandino G, Shaul Y. The Hippo tumor suppressor pathway: a report on “The
Second Workshop On The Hippo tumor suppressor pathway”. Cell Death Differ.
2011 Aug;18(8):1388-90.
10) 5th Mutant p53 Workshop: “From bench to bedside across mouse models”, Ariccia (Rome), Italy, 24th May, 2011. Published: Blandino G, Deppert W, Hainaut P,
Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. “Mutant p53 protein,
master regulator of human malignancies: a report on the fifth Mutant p53
Workshop”. Cell Death Differ. 2012 Jan;19(1):180-3.
11) Keystone Symposium “The HIPPO Tumor Suppressor Network: from organ size control to stem cells and cancer”, Monterey, CA, USA 19-23 May 2013 (Organizers: Dr. Sudol, Dr. Blandino, Dr. Halder, Dr. McNeil).
Grant Funding
Principal Investigator
“ Epigenetic and metabolic alterations in cancer pathogenesis” Blandino G, PI; Euros
400,000, Italian Ministry for Research and University 2011-2014
“Profile of microRNA expression and CpG Island methylation in tissue samples from
mesothelioma patients” Blandino G, PI; Euros 600,000 Italian National Institute for
Occupational Disease Prevention 2010-2012
European Union 6th Framework “Integrated Project Active p53”, Blandino G,
Scientific Coordinator ; Euros 6,000,000.000 2004-2009 (extended 2012)
“Molecular signature as predictor of breast cancer occurrence” Blandino G, PI; Euros
150,000 Veronesi Foundation 2010-2012
“p53 family interaction network as a target of anti-tumoral peptide therapy” Blandino
G, PI; Euros 115.000 Pascale Foundation. 2008-2011
“Exploring trascriptional activity of gain of function Mutant p53 protein” Blandino G,
PI; Euros 330,000 AIRC. 2007-2011
“Linking transcriptome to proteome: Functional oncogenomics for diagnosis and
treatment of human cancer” Blandino G, PI; Euros 3,000,000 AIRC 2004-2011
CV Dr. Giovanni Blandino, M.D., MSc - Page 9 “Global epigenomic profiling of normal and diseased cells for the diagnosis of normal
and diseased cells for diagnosis of hematological malignancies” Blandino G, Co-
Investigator; Euros 120,000 European Institute of Oncology 2010-2012
“New peptides as cell cycle regulators in chemotherapy for epithelial and skin cancer”
Blandino G, Co-Investigator; Euros 150,000 Italian Institute for Dermatology 2007-
2011
European Unnion 6th Framework: “Research unit of the Integrated Project “Mutp53”
Prof. Klas Wiman and Prof. Moshe Oren (PI); Blandino G, Co-Investigator; Euros
240.933,50 2004

Grant Support for the conduction of the laboratory
The work in Dr. Blandino’s laboratory is supported by: Italian Ministry of Health: Euros 122,000.00 Italian Association for Cancer Research (AIRC): Euros 110,000.00 Italian Ministry for Research and University: Euros 435,000.00
Patents, National and International

1. Inventors: Giovanni Blandino, Gennaro Citro, Rossella Maria Galati,
Alessandra Verdina.
Number and date of deposit in Italy: MI2004A002227, 19 November 2004
This invention allows "Peptides to be able to break 53/p63, m-p53/p73 and m-
p53/respective isoform proteins complex formed in the tumor cells and there
uses in the pharmacological field". In addition, this invention uses a method that
provokes the disruption of complex proteins found in the cancer cell lines in
vitro. Furthermore, these peptides are used in preparing anti-cancer medicine.
Iter: 2007 Deposited permit request on a National/European level + permit
requested in Israel, Singapore, the USA and EU. 2008 permit request made in
Germany. 2010 Entered PCT national phase in the USA. 2011 Granted the PCT
process in Japan
2. Inventors: Giovanni Blandino, Gennaro Citro, Sabrina Strano, Silvia Di
Agostino.
Number and date of deposit in Italy: RM 2009A232 del 11/05/2009.
The present invention concerns peptide able to disrupt the protein complex
between HIS273 mutated p53 protein and oncosuppressive p73 protein in tumor
cells and uses hereof in medical field. More particularly, the present invention
concerns a SIMP peptide (Short-interfering mutant p53 peptides) suitable to
CV Dr. Giovanni Blandino, M.D., MSc - Page 10 disrupt the protein complexes within tumor cells resulting from m-p53 and p73 proteins selectively in tumors wherein m-p53 contains HIS273 mutation. Iter: 2010 deposited international permit request
Publications in Peer-Reviewed Journals:

1) Callari D, Gasso G, Blandino G, Billitteri A. Azione del retinolo su colture di
hepatoma H4. Boll. Soc. It. Biol. Sper. N11., 1989. 2) Callari D, Blandino G, Saccone V, D'Amico C, Billitteri A. Azione del retinolo sul
recupero di cellule vitali e sul potenziale clonogenico di cellule HTC ipertermizzate in vitro. Boll. Soc. It. Biol. Sper. N.12, 1992. 3) Callari D, Blandino G, Saccone V, D'Amico C, Billitteri A. Azione dell'ipertermia e
del trattamento con retinolo in vitro sull'adesività alla laminina ed alla fibronectina delle cellule HTC. Boll. Soc. It. Biol. Sper. N.12; 1992. 4) Callari D, Strano S, Blandino G, Saccone V, and Billitteri A. Adhesion to some
extracellular matrix components of heat-treated HTC hepatoma cells. J. Exp. Clin. Cancer. Res. 13: 2, 1994.
5) Strano S, Callari D, Billitteri A, and Blandino G. Fibronectin and Vitronectin
Adhesion enhancement during U937 cells differentiation induced by IL-6 and LIF. J. Exp. Clin. Cancer Res., 13, 4, 1994. 6) Soddu S, Blandino G, Citro G, Scardigli R, Piaggio G, Ferber A, Calabretta B, and
Sacchi A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood, 83, 8, 1994. 7) Strano S, and Blandino G. Apoptosis: cell death or suicide. This is the problem! J.
8) Blandino G, Scardigli R, Rizzo MG, Crescenzi M. Soddu S, and Sacchi A. Wild-
type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene, 10, 731-737, 1995. 9) Soddu S, Blandino G, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M, and
Sacchi A. WT-p53 induces diverse effects in 32D cells expressing different oncogenes. Molecular and Cellular Biology, 16, 2, 487-495, 1996. (The two first authors contributed equally to this work). 10) Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G,
Cimino L, Crescenzi M, and Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. The Journal of Cell Biology, 134, 1, 193-204, 1996. 11) Martinelli R, Blandino G, Scardigli R, Crescenzi M, Lombardi D, Sacchi A, and
CV Dr. Giovanni Blandino, M.D., MSc - Page 11 Soddu S. Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. Oncogene 15, 607-611, 1997 12) Shaulian E, Resnitzky D, Shifman O, Blandino G, Amsterdam A, Yayon A, and
Oren M. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 15, 2717-2725, 1997. 13) Scardigli R, Bossi G, Blandino G, Crescenzi M, Soddu S, and Sacchi A. Exogenous
wt-p53 overexpression does not affect normal hematopoiesis: basis for bone marrow purging? Gene Therapy 4, 1371-1378, 1997. 14) Blandino G, and Strano S. Bcl-2: the pendolum of the cell fate. J. Exp. Clin. Cancer.
15) Rizzo M.G, Zepparoni A, Cristofanelli B, Scardigli R, Crescenzi M, Blandino G,
Giuliacci S, Ferrari S, Soddu S and Sacchi A. Wtp53-action in human leukemia cell lines corresponding to different stages of differentiation. British Journal of Cancer 77, 1429-1438, 1998 16) Wang Y, Blandino G, Oren M, and Givol D. Induced p53 expression in lung cancer
cell line promotes cell senescence and differently modifies the cytotoxicity of anticancer drugs. Oncogene 17, 1923-1930, 1998. 17) Blandino G, Levine AJ, and Oren M. Mutant p53 gain of function: differential
effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18, 477-485, 1999. 18) Wang Y, Blandino G, and Givol D. Induced p21 waf1 expression in H1299 cell line
promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene 18, 2643-2649, 1999. 19) Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73α and their
collaboration to induce apoptosis. Nature 399, 809-813, 1999. 20) Cerone M.A, Marchetti A, Bossi G, Blandino G, Sacchi A, and Soddu S. p53 is
involved in the differentiation but not in the differentiation-associated apoptosis of myoblast. Cell Death and Differentiation 7, 506-508, 2000 21) Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine A.J, Sacchi A, Cesareni G, Oren M and Blandino G. Physical and functional interaction
between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503-
29512, 2000
22) Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A and Blandino G.
From p63 to p53 across p73. FEBS Letters, 490, 163-170, 2001. 23) Strano S, Munarriz E, Rossi M, Cristofanelli B, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G and Blandino G. Physical interaction with Yes-
CV Dr. Giovanni Blandino, M.D., MSc - Page 12 associated protein (YAP) enhances p73 transcriptional activity. J. Biol. Chem., 276, 15164-15173, 2001. 24) Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, and Blandino
G. The transcriptional repressor ZEB regulates p73 expression at the cross-road
between proliferation and differentiation. Mol. Cell. Biol., 24, 8461-8470, 2001.
25) Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole P, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, and Levrero M. DNA damage-
dependent acetylation of p73 dictates the selective activation of apoptotic target
genes. Mol. Cell, 9, 175-186, 2002.
26) Le Bras M, Delattre V, Bensaad K, Blandino G, and Soussi T. Monoclonal
antibodies raised against Xenopus p53 interact with human p73. Oncogene,14, 1304-1308, 2002. 27) Morena A.R, Riccioni S, Marchetti A, Tartaglia Polcini A, Mercurio A.M, Blandino
G, Sacchi A, and Falcioni R. Expression of β4 integrin subunit induces monocytic
differentiation of 32D/v-Abl cells. Blood, 100, 96-106, 2002
28) Strano S, Fontemaggi G, Costanzo A, Rizzo M.G, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M and Blandino G. Physical interaction with human
tumor derived p53 mutants inhibits p63 activities. J. Biol Chem. 277, 18817-18826,
2002
29) Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, and Blandino G. Identification of direct p73 target genes combining
DNA microarray and chromatin immunoprecipitation analyses. J. Biol Chem. 277,
43359-43368, 2002
30) Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, and Del Sal G. The Prolyl-Isomerase Pin1 reveals a new
mechanism to control p53 functions following genotoxic insults. Nature, 419, 853-
857, 2002
31) Bensaad K, Le Bras M, Unsal K, Strano S, Blandino G, Tominaga O, Rouillard D
and Soussi T. Change of conformation of the DNA binding domain of p53 is the only key element for binding and interfering with p73. J. Biol. Chem. 278, 10546-10555, 2003. 32) Strano S, and Blandino G. p73-mediated chemosensitivity: a preferential target of
oncogenic mutant p53 proteins. Cell Cycle 2, 348-349, 2003. 33) Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, Blandino G, Balsano C.,
Lavia P, and Levrero M. p73 is regulated by phosphorylation at the transition G2/M. J. Biol. Chem., 278, 49196-49202, 2003. 34) Di Stefano V, Blandino G, Sacchi A, Soddu S, and G. D’ Orazi. HIPK2 counteracts
MDM2 inhibition of p53 by interfering with its ubiquitination and nuclear export. Oncogene 231, 5185-5192, 2004. CV Dr. Giovanni Blandino, M.D., MSc - Page 13 35) Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, Blandino G,
and Del Sal G. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Molecular Cell, 14, 625-636, 2004. 36) Blandino G and M. Dobbelstein. p73 and p63-why do we still need them? Cell
37) Rizzo M.G, Giombini E, Diverio D, Vignetti M, Testa U, Sacchi A, Lo Coco F, and Blandino G. Analysis of p73 expression in acute myeloid leukemias: lack of DN-
p73 expression is a frequent feature of acute promielocytic leukemia. Leukemia 18,
1804-1809, 2004.
38) Dobbelstein M, Strano S, Roth J, and Blandino G. p73-induced apoptosis: a
question of compartments and cooperation. Biochem. Biophys. Res. Commun, 331, 688-693, 2005. 39) Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, and Blandino G. The
transcriptionl co-activator Yes-associated protein drives p73 gene-target specificity
in response to DNA damage . Molecular Cell. 18, 447-459, 2005.
40) Fontemaggi G, Gurtner A, Damalas A, Higashi Y, Sacchi A, Strano S, Piaggio G and Blandino G. δEF1 repressor controls selectively p53 family members during
differentiation. Oncogene. Nov. 10; 24(49):7273-80, 2005.
41) Merlo P, Fulco M, Costanzo A, Mangiacasale R, Strano S, Blandino G, Taya Y,
Lavia P. and Levrero M. p73 role in mitotic exit. J. Biol. Chem. 280, 30354-30360, 2005. 42) Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, and Sacchi A. Mutant p53 gain
of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene Jan 12 ; 25 (2):304-9, 2006. 43) Belloni L, Moretti F, Damalas A, Costanzo A, Blandino G, and Levrero M. ∆Np73α
protects myogenic cells from apoptosis. Oncogene Jun.15 ;25 (25):3606-12, .2006. 44) Lapi E, Iovino A, Fontemaggi G, Soliera R, Iacovelli S, Sacchi A, Rechavi G, Givol D, Blandino G* and Strano S. S100A2 is a direct transcriptional target of p53
homologues during keratynocyte differentiation (*corresponding author) Oncogene
Jun.22 ;25 (26):3628-37, 2006.
45) Giombini E, Blandino G, Sacchi A, Lo Coco F, and Rizzo M.G. The complexity of
p73 isoforms in human neoplasia. Gene Ther. Mol. Biol. 9:1-16, 2005. 46) Hoshino M, Qi M, Yoshimura M, Miyashita T., Tagawa K, Wada Y, Enokido Y, Marubuchi S, Harjes P, Arai N, Oyanagi K, Blandino G, Sudol M, Rich T, Kanazawa
I, Wanker E.E, Saitoe M, and Okazawa H. Transcriptional repression induces a
slowly progressive atypical neuronal death associated with changes of YAP isoforms
and p73. J. Cell Biology Feb. 589-604, 2006.
CV Dr. Giovanni Blandino, M.D., MSc - Page 14 47) Di Agostino S, Strano S, Emiliozzi V, Sacchi A, Blandino G*, Piaggio G. Gain of
function of mutant p53: the mutant p53/NFY protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. (*corresponding author) Cancer Cell Sep.10 (3):191-202, 2006. 48) Strano S, Dell’Orso S, Mongiovì A, Monti O, Lapi E, Di Agostino S, Fontemaggi G and Blandino G. Mutant p53 proteins: between loss and gain of function. Head and
Neck 29:488-96, 2007
49) Strano S, Dell’Orso S, Di Agostino S, Fontemaggi G, Sacchi A, and Blandino G.
Mutant p53: an oncogenic transcription factor. Oncogene 26:2212-9, 2007. 50) Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Kalis M, Levrero M, Strano S, Gorgoulis W.G, Rotter V, Blandino G, Oren M. Mutant p53 enhances
NF-kB activation by tumor necrosis factor alpha in cancer cells. Cancer Research
67:2396-401, 2007
51) Blandino G, Fanciulli M, Levrero M, Piaggio G. The Post Genomic Era: Workshop
on Chromatin Immunoprecipitation related techniques. Cell. Death and Diff. 14:1390-1391, 2007 52) Mainardi S, Palescandolo E, Fontemaggi G, Diverio D, Grignani F, Testa U, Sacchi A, Lo Coco F, Levrero M, Blandino G* and Rizzo MG. DNp73 is a transcriptional
target of PML/RARα oncogene (*corresponding author) Cell Death and
Differentiation 14:1968-71, 2007
53) Strano S, and Blandino G. YAP meets tumor suppression. Mol. Cell, 27:863-4,
54) Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G., Givol D, D'Orazi G. Reversible
dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2
knockdown. Cancer Res. May 15;68(10):3707-14, 2008
55) Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G., Sacchi A. Conditional RNA interference in vivo to study mutant p53
oncogenic gain of function on tumor malignancy. Cell Cycle. Jun 15;7(12):1870-9,
2008
56) Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G. The disruption of the protein complex mutantp53/p73
increases selectively the response of tumor cells to anticancer drugs. Cell Cycle. Nov
1;7(21):3440-7, 2008
57) Blandino G. Mitosis poisons p53. Cell Cycle. Nov 1;7(21), 2008
58) Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G. PML, YAP, and p73 are components of a
CV Dr. Giovanni Blandino, M.D., MSc - Page 15 proapoptotic autoregulatory feedback loop. Mol Cell. Dec 26;32(6):803-14, 2008 59) Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G.
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics. May;9(3):200-7, 2008 60) Benassi B, Strano S, Blandino G. Tetraploidy triggers mitochondria. Cell Cycle.
61) Blandino G, Moll UM. p63 regulation by microRNAs. Cell Cycle. May
62) Haupt S, Di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G, Haupt Y. Promyelocytic leukemia protein is required for gain of
function by mutant p53. Cancer Res. Jun 1;69(11):4818-26, 2009
63) Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: at the crossroad between
transformation and tumor suppression. Cell Cycle. Jan 1;8(1):49-57, 2009 64) Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, Blandino G, Mottolese M, Falcioni R. Negative regulation of
beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53
impairs tumor progression. Cancer Res. Jul 15;69(14):5978-86, 2009
65) Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, Blandino G.
Metformin, diet and breast cancer: an avenue for chemoprevention. Cell Cycle. Aug 15;8(16):2661, 2009 66) Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F, Blandino G, Levrero M, Rizzo
MG. A restricted signature of miRNAs distinguishes APL blasts from normal
promyelocytes. Oncogene. Nov 12;28(45):4034-40, 2009
67) Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G. The
execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-
angiogenesis. Nat Struct Mol Biol. Oct;16(10):1086-93, 2009
68) Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M, Piacentini M, Blandino G, Costanzo A, Sakaguchi K, Tuosto L.
Characterization of a new cancer-associated mutant of p53 with a missense mutation
(K351N) in the tetramerization domain. Cell Cycle. Oct 15;8(20):3396-405, 2009
CV Dr. Giovanni Blandino, M.D., MSc - Page 16 69) Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Lauria R, Malorni L, Muti P. Urinary estrogen metabolites
and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res.
Oct 8;28:135, 2009
70) Blandino G, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor
pathway: a brainstorming workshop. Sci Signal. Nov 3;2(95):mr6, 2009 71) Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of
the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. Mar
16;17(3):273-85, 2010
72) Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalg Ri, Tarcic G, Bossel N, Zeisel A, Amit I, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano, Blandino G,
Børresen-Dale A, Pilpel Y, Yakhini Z, Segal E and Yarden Y. EGF Decreases the
abundance of microRNAs that restrain oncogenic transcription factors. Sci. Signal.
Jun 1;3(124):ra43, 2010
73) Cioce M, Gherardi S, Viglietto G, Strano S, Blandino G, Muti P and Ciliberto G.
Enriched mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like targeting drugs. Cell Cycle. Jul 15;9(14):2878-87, 2010 74) Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Floridi A, Passananti C, Blandino G, and Fanciulli M.
Che-1 depletion inhibits mutant p53 expression and activates p73-dependent
apoptsosis by inducing endogenous DNA damage in human breast cancer. Cancer
Cell. Aug 9;18(2):122-34, 2010
75) Slee E, Benassi B, Goldin R, Zhong S, Blandino G, and Lu X. Phosphorylation of
Ser312 contributes to tumour suppression by p53 in vivo. Proc Natl Acad Sci U S A. Nov 9;107(45):19479-84, 2010 76) Santoro R, Blandino G. p53: The pivot between cell cycle arrest and senescence.
77) Fontemaggi G, Dell’Orso S, Muti P, Blandino G and Strano S. Id2 gene is a
transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle. Jun 15;9(12):2464-6, 2010 78) Strano S and Blandino G. Stability strengths oncogenic activity. Cell Cycle. Apr
79) Goeman F, Blandino G. Novel insights into the cytoplasmic functions of p53. Cell
80) Dell’Orso S, Ganci F, Strano S, Blandino G, and Fontemaggi G. ID-4: a new player
in the cancer arena. Oncotarget. May;1(1):48-58, 2010 CV Dr. Giovanni Blandino, M.D., MSc - Page 17 81) Dell’Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Damalas A, Levrero M, Strano S, Rotter V, Oren M and Blandino G. ChIP on chip analysis of in
vivo mutantp53 binding to selected gene promoters. OMICS. May;15(5):305-12,
2011
82) Muti P, Benassi B, Falvo E, Santoro R, Galanti S, Citro G, Carrubba G, Blandino G,
and Strano S. Omics underpins novel clues on VDR chemoprevention target in breast cancer. OMICS. Jun;15(6):337-46, 2011 83) Ganci F, Conti S, Fontemaggi G, Manciocco V, Donzelli S, Covello R, Muti P, Strano S, Blandino G, Spriano G. Allelic expression imbalance of TP53 mutated
and polymorphic alleles in head and neck tumors. OMICS. Jun;15(6):375-81, 2011
84) Testoni B, Guerrieri F, Gerbal-Choine S, Blandino G and Levrero M. p53-paralog
DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 Polycomb Group transcriptional repressor. Oncogene. Jun 9;30(23):2670-8. doi: 10.1038/onc.2010.635, 2011 85) Sieri S, Muti P, Agnoli C, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G,
Contiero P, Schunemann H, Krogh V. Prospective study on the role of glucose
metabolism in breast cancer occurrence. Int J Cancer. Feb 15;130(4):921-9, 2011
86) Testoni B, Voellenke C, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M.
Chromatin dynamics of gene activation and repression in response to ifn{alpha} reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem. Jun 10;286(23):20217-27, 2011 87) McNeill H, Sudol M, Halder G, Strano S, Blandino G, Shaul Y. Meeting Report
The Hippo tumor suppressor pathway: a report on the Second Workshop on the Hippo tumor suppressor pathway. Cell Death and Differentiation. Aug;18(8):1388-90. doi: 10.1038/cdd.2011.61, 2011 88) Di Agostino S, Strano S, Blandino G . YAP1 (Yes-associated protein 1, 65kDa).
Atlas Genet Cytogenet Oncol Haematol. January 2010 89) Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Soussi S, Mazzoni C, Blandino G and Tuosto L. The cancer-associated K351N mutation
affects the ubiquitination and the translocation to mitochondria of p53 protein. J.
Biol. Chem. Sept 27, asdoi:10.1074/jbc.M111.279539, 2011 (Epub ahead of print)
90) Botti E, Spallone G, Moretti F, Marinari B, Pinetti V, Galanti S, De Meo PD, De Nicola F, Ganci F, Castrignanò T, pesole G, Chimenti S, Guerrini L, Fanciulli M,
Blandino G, Karin M, Costanzo A. Developmental factor IRF6 exhibits tumor
suppressor activity in squamous cell carcinomas. Proc Natl Acad Sci U S A. Aug
16;108(33):13710-5, 2011
91) Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D’Alessia D, Muti P, Blandino G, Sperduti I, Pinnarò P. Dose and polymorphic genes xrcc1, xrcc3, gst
paly a role in the risk of article developing erythema in breast cancer patients
following single shot partial breast irradiation after conservative surgery. BMC
CV Dr. Giovanni Blandino, M.D., MSc - Page 18 92) Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser
phosphorylation and prevents DNA damage accumulation. Oncogene Oct 17. doi: 10.1038/onc.2011.469, 2011(Epub ahead of print) 93) Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V,
Wiman K and Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop. Cell Death & Differentiation. Jan;19(1):180-3, 2012 94) Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino
G, Cioce M. SASP mediates chemoresistance and tumor-initiating-activity of
Mesothelioma cells. Oncogene Oct 24. doi: 10.1038/onc.2011.485, 2011 (Epub ahead
of print)
95) Cioce M, Canino C, Muti P, Strano S, Blandino G. Butein impairs the pro-
tumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle. Jan 1;11(1):132-40, 2012 96) Benassi B, Flavin R, Marchionni L, PanY, Chowdhury D, Marani M, Strano S, Muti P, Blandino G, and Loda M. c-Myc is activated via USP2a-mediated modulation of
microRNAs in prostate cancer. Cancer Discov. 2012 Mar;2(3):236-247 (co-
corresponding author)
97) Cioce M, Blandino G. PGC1α Confers Specificity - Metabolic Stress and p53-
Dependent Transcription. Molecular Cell. Nov 18;44(4):515-6, 2011 98) Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G. microRNA-128-2 targets the transcriptional repressor E2F5
enhancing mutant p53 gain of function. Cell Death and Differentiation
Jun;19(6):1038-48, 2012
99) Valenti F, Fausti F, Biagioni F, Fontemaggi G, Shay T, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S. Mutant p53 oncogenic functions are sustained
by plk2 kinase through an autoregulatory feedback loop. Cell Cycle. Dec
15;10(24):4330-40, 2012 (co-corresponding author)
100) Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Bergamo P, Anichini A, Sabapathy K, McCubrey J, Ricciardi MR, Tafuri A,
Blandino G, Orlandi A, Cognetti F, De Maria R, Del Bufalo D, Milella M. The
mitogen activated protein kinase (MARK) cascade controls phosphatase and tensin
homolog (PTEN) expression through multiple mechanisms. Journal of Molecular
Medicine. Jan 4, 2012
101) Falvo E, Strigari L, Citro G, Giordano C, Boboc G, Fabretti F, Bruzzaniti V, Bellesi L, Muti P, Blandino G, Pinnarò P. SNPs in DNA repair or Oxidative Stress
Genes and Late Subcutaneous Fibrosis in Patients following a Single Shot Partial
Breast Irradiation. JECCR. Jan 24;31:7, 2012
CV Dr. Giovanni Blandino, M.D., MSc - Page 19 102) Blandino G*, Valerio M*, Cioce M*, Mori F, Casadei L, Pulito C, Sacconi A,
Biagioni F, Cortese G, Galanti S, Manetti C, Gennaro Citro G, Muti P, Strano S. Metformin elicits anticancer effects through the sequential modulation of DICER, microRNAs and c-MYC. Nat Commun. 2012 May 29;3:865 (corresponding author) 103) Cordelli, E, Eleuteri, P, Grollino, M, Benassi, B, Blandino, G, Bartoleschi, C,
Pardini, M, Di Caprio, E, Spanò, M, Pacchierotti, F, Villani, P. Direct and delayed X-ray induced DNA damage in male mouse germ cells. Environ Mol Mutagen. 2012 Jul;53(6):429-39 104) Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso
G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E and Blandino G. miR-
10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumors.
EMBO Mol Med. 2012 Nov;4(11):1214-29.
105) Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Di Agostino S, Cambria A.M., Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V,
Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E,
Garofalo A and Blandino G. miR-204 targets Bcl-2 expression and enhances
responsiveness of gastric cancer. Cell Death Dis. 2012 Nov 15;3:e423
106) Fausti F, Di Agostino S, Sacconi A, Strano S, Blandino G. Hippo and rassf1a
Pathways: A Growing Affair. Mol Biol Int. 2012;2012:307628 1. 107) Santoro R, Marani M, Blandino G, Muti P, Strano S. Blockage of melatonin
receptors impairs p53-mediated prevention of DNA damage accumulation. (Carcinogenesis, published online 25th Jan 2013). 108) Santoro R, Marani M, Blandino G, Muti P, Strano S. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. (Carcinogenesis, published online 25th Jan 2013).
Chapters in Books
1. Rizzo M.G, Soddu S, Crescenzi M, Blandino G, Scardigli R, Coen S, Sacchi A.
Wild-type p53 overexpression diversely affects different leukemia cells. Proceedings of the XVI International Cancer Congress 1994. New Delhi (India), October 30-November 5, 1994. Monduzzi Editore 2. Monti O, Damalas A, Strano S, and Blandino G. p73, p63 and mutant p53: members
of protein complexes floating in cancer cells. Book for “25 years of p53 research” by Kluwer Academic Publishers. 2005 3. Blandino G. Gain of function p53. Encyclopedia of Cancer, 2nd edition by Springer
CV Dr. Giovanni Blandino, M.D., MSc - Page 20 4. Ganci F, Sacconi A, Manciocco V, Spriano G, Fontemaggi G, Blandino G.
Molecular genetics and biology of head and neck squamous cell carcinoma: implications for diagnosis, prognosis and treatment. Head and Neck Cancer (ISBN 979-953-307-914-0). 2012 5. Blandino G and Fontemaggi G. Id4 (Inhibitor of DNA binding). Encyclopedia of
6. Goeman F, Fontemaggi G, Blandino G. ChIP-on-chip to identify mutant p53
targets. p53 Protocols: Second edition. Humana Press (Springer). 2012 7. Donzelli S, Strano S, Blandino G. Yap and p73: a matter of mutual specificity in
tumor suppression. The Hippo Signaling pathway and cancer. Springer (in press, 2012)


Letters (peer-reviewed)
1) Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, Blandino G.
Metformin, diet and breast cancer: An avenue for chemoprevention, Cell Cycle. 8:16, 1-1; 15 August, 2009
Invited Presentations (selected)

National and International Meetings (selected)

1) Speaker: The Mutp53 Consortium Kick-Off Meeting, Lillehammer, Norway, 2004 2) Speaker: First IEO-IFOM Cancer Meeting, Milan, Italy 2004 3) Speaker: 26th Meeting of the European Study Group for Cell Proliferation (ESGCP), 4) Speaker: OECI 25th Annual Meeting, Berlin, Germany 2004 5) Speaker: The Active p53 Consortium Kick-Off Meeting, Ghent, Belgium 2004 6) Speaker: Life Sciences FP6 European Research Proposals Meeting, Poland 2005 7) Speaker: P53 Marathon, Ein Gedi, Israel, 2005 8) Speaker: 2nd IFOM –IEO Cancer Meeting, Milan, Italy 2006 9) Speaker: International p53 Workshop, New York, USA 2006 CV Dr. Giovanni Blandino, M.D., MSc - Page 21 10) Speaker: P53 Marathon, Frascati, Italy 2006 11) Speaker: XIV Telethon Scientific Convention, Salsomaggiore, Italy 2007 12) Speaker: 3rd International p73/p63 Workshop, Rome, Italy 2007 13) Speaker: World Stress Conference, Budapest, Hungary 2007, August 25th. Title: 14) Speaker: FEBS Workshop: The Biology of Modular Protein Domains, Seefeld, Austria 2007, September 11th. Title: “The WW domain of YAP is critical in the execution of p73-mediated apoptosis in response to DNA damage” 15) Speaker: Cancer Therapeutics: The Road Ahead, Capri, Italy 2007, October 8th. Title: “Mutant p53 Gain of Function: SIMPs-mediated Disruption of the Protein Complex mutp53/p73 Enhances Selectively the Chemosensitivity of Mutant p53 Tumor Cells” 16) Speaker: P53 Marathon. Deregulating the p53 Network : Origin and Consequences of TP53 mutations, Lyon, France 2007, November 14th. Title: “Mutant p53: an oncogenic transcription factor” 17) Speaker: Era of Hope Department of Defense Breast Cancer Research Program Meeting, Baltimore, USA 2008, June. 18) Speaker. Title: “The Potential of Metformin Use in Breast Cancer”, Turin, Italy, 19) Speaker: P53 Marathon, Acre, Israel 2009, March 27th. Title: “Mutant p53 triggers an oncogenic autoregulatory feedback loop”. 20) Speaker: University of Oxford, 2009, November 16th. Title: “Oncogenic cross-talks 21) Speaker:, 3rd International p63/73 Workshop, Rome, Italy, 2009, March 21st. Title: “Reactivation of p73 is dangerous for tumour cells”. 22) Chair & Speaker: The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, Rome, Italy, 2009, April 22nd. Title: “YAP bridges p73 and PML pro-apoptic pathways” 23) Chair & Speaker: The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, Rome, Italy, 2010, November 3rd. Title:“Role of YAP in apoptosis and senescence as tumour suppression mechanisms”, 24) Speaker: Karolinska Institutet, Stockolm, 2010,. Title: “Oncogenic cross-talks in 25) Speaker: SIBBM seminar: Frontiers in Molecular Biology, University of Padua, 2010, June 4th. Title: “Molecular determinants in breast cancer”. CV Dr. Giovanni Blandino, M.D., MSc - Page 22 26) Speaker: University of Trieste, School of Molecular Biomedicine, 2011, March 30th. Title: “Exploring tumour chemoresistance: miRNAs and cancer stem cells”. 27) Speaker: Institute San Raffaele in Milan, Department of Experimental Onocology, 2011. Title: “Exploring tumor chemoresistance: miRNAs and cancer stem cells” 28) Speaker: 5th Mutant p53 Workshop: “From bench to bedside across mouse models”, Rome, Italy, 2011, May 23rd. Title: “Oncogenic transcriptional activity of mutant p53”. 29) Chair: Mutant p53 activities in vivo: 5th Mutant p53 Workshop: “From bench to bedside across mouse models”, Rome, Italy, 24th May, 2011. 28) Speaker: 53rd Annual Meeting of the Italian Cancer Society: “Back to the future”, Translating cancer research from bedside to bench and back, Torino, Italy, 2011, October 22nd. Title: “The Hippo-YAP pathway in organ size control tumorigenesis”.

Source: http://www.activep53.eu/OTLWS/files/CV.pdf